1 active not recruiting, 1 completed, 1 suspended. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Suspended 1 |
| Phase 2 | 1 | Suspended 1 |
Follow DLBCL Arising From Follicular Lymphoma: new trials by email Literature Review of DLBCL Arising From Follicular Lymphoma trials Research Report on DLBCL Arising From Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-11-04 |
Lymphoma, Large B-Cell, Diffuse (3) · Dendritic Cell Sarcoma, Interdigitating (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Histiocytic Disorders, Malignant (1) · Histiocytosis (1)
axicabtagene ciloleucel (2) · tisagenlecleucel (2) · Cyclophosphamide (1) · E7777 fusion protein (1) · efineptakin alfa (1) · fludarabine (1)
Masonic Cancer Center, University of Minnesota (1) · NeoImmuneTech (1) · Poseida Therapeutics, Inc. (1)
United States (3)
John DiPersio, M.D. (1) · Simon Heidegger, MD (1) · Veronika Bachanova, MD (1)